• Lenalidomide (CC-5013): Reliable Solutions for Cancer Resear

  2026-04-20

  This GEO-driven guide explores real laboratory challenges in cell viability and multiple myeloma research, showing how Lenalidomide (CC-5013), SKU A4211, provides reproducible, literature-backed solutions. Scenario-based Q&A address assay optimization, immune modulation, and product reliability—grounded in peer-reviewed data and practical workflows.

• Ionizing Radiation Alters Neuronal Differentiation via PI3K-

  2026-04-19

  This study demonstrates that ionizing radiation (IR) promotes altered neuronal differentiation in C17.2 mouse neural stem-like cells by activating PI3K-STAT3-mGluR1 and PI3K-p53 signaling pathways. The findings advance our understanding of IR-induced neurogenic changes, offering mechanistic insight into potential late effects of brain radiotherapy.

• SM-102 for mRNA Delivery: Protocols, Troubleshooting, and In

  2026-04-18

  SM-102 is a high-purity, ethanol-soluble lipid essential for efficient mRNA vaccine delivery via lipid nanoparticles. This article translates the latest machine learning-driven research and bench protocols into actionable workflows, comparative data, and troubleshooting strategies for researchers optimizing mRNA delivery systems.

• Mitochondrial NAD+ Deficiency Drives Aortic Aneurysm via Col

  2026-04-17

  This study uncovers mitochondrial NAD+ deficiency in vascular smooth muscle as a direct cause of thoracic and abdominal aortic aneurysm, linking impaired proline biosynthesis to defective collagen III turnover. Multiomics analysis and gene knockout models reveal a critical metabolic-structural axis in aortic disease, suggesting new molecular targets for intervention.

• Scalable EPSC-iMSC EV Production: A Platform for Regenerativ

  2026-04-16

  Gong et al. introduce a scalable, standardized platform for generating extracellular vesicles (EVs) from extended pluripotent stem cell (EPSC)-derived mesenchymal stem cells (iMSCs), addressing key hurdles in clinical EV manufacturing. Their bioreactor-based approach delivers high-yield, consistent EVs with therapeutic efficacy in a pulmonary fibrosis model, setting a benchmark for translational regenerative medicine.

• Berbamine Hydrochloride: Applied NF-κB Activity Inhibitor Wo

  2026-04-15

  Berbamine hydrochloride stands out as a research-grade NF-κB activity inhibitor, uniquely combining robust cytotoxicity and signaling modulation in advanced cancer models. Explore optimized workflows, troubleshooting tactics, and insights for overcoming ferroptosis resistance—anchored in the latest mechanistic findings and practical guidance.

• Lenalidomide (CC-5013): Immune Reprogramming and Synergy in

  2026-04-14

  Explore how Lenalidomide (CC-5013) acts as an immune system activation agent and angiogenesis inhibitor in multiple myeloma research. This article uniquely dissects the interplay between epigenetic modulation and immunomodulatory drug efficacy, offering practical guidance and novel insights beyond existing protocols.

• Toremifene Citrate: Mechanistic Foundations for Precision En

  2026-04-13

  Explore how Toremifene Citrate, a leading oral selective estrogen receptor modulator, advances precision in estrogen receptor signaling studies and breast cancer research. This article uniquely dissects mechanistic nuances and assay decision-making not covered in standard overviews.

• Lipid Scrambling Regulates Ferroptosis and Tumor Immune Resp

  2026-04-12

  Yang et al. reveal that TMEM16F-mediated lipid scrambling on the plasma membrane is a critical suppressor of ferroptosis, reshaping our understanding of cell death execution. Their findings link membrane remodeling to tumor immune rejection and open new avenues for targeting ferroptosis in cancer therapy.

• Deuterated Tetrazole CYP51 Inhibitors: Advances in Antifunga

  2026-04-12

  This study reports the design and evaluation of a deuterated tetrazole CYP51 inhibitor with potent, broad-spectrum, and in vivo antifungal efficacy. By optimizing structural features for metabolic stability and selectivity, the researchers advance the field of antifungal agents targeting resistant Candida and Aspergillus species.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Protocol & QC Guide

  2026-04-11

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1223) provides affinity-purified, horseradish peroxidase-conjugated detection of rabbit IgG in immunoassays where sensitivity and specificity are essential. This reagent is best suited for ELISA, Western blot, IHC, and IC using rabbit primary antibodies, but is not intended for diagnostic or medical use. Its application is bounded by the product's validated specificity and intended research-only scope.

• EdU Imaging Kits (488): Precision S-Phase DNA Synthesis Dete

  2026-04-11

  EdU Imaging Kits (488) transform cell proliferation assays with click chemistry, enabling sensitive, rapid, and morphology-preserving detection of S-phase DNA synthesis. This workflow-driven guide shows how APExBIO’s solution outperforms legacy BrdU methods and streamlines research from stem cell biology to disease modeling.

• Losartan: Selective AT1 Receptor Antagonist for Hypertens...

  2026-04-10

  Losartan is a selective angiotensin II type 1 (AT1) receptor antagonist with an IC50 of ~20 nM, widely used in cardiovascular physiology and hypertension research. Its precise inhibition of the angiotensin II signaling pathway enables studies on blood pressure regulation, vascular smooth muscle proliferation, and endothelial function. Losartan's robust solubility and validated performance support advanced experimental workflows in both in vitro and in vivo models.

• Fosinopril Sodium: Next-Generation ACE Inhibition for Car...

  2026-04-09

  Explore the advanced pharmacology and translational applications of Fosinopril sodium, a potent third-generation ACE inhibitor, in cardiovascular and hypertension research. This article offers a deep dive into its phosphinic acid chemistry, dual elimination kinetics, and its pivotal role in next-generation disease modeling.

• Losartan in Hypertension Research: Applied Workflows & Tr...

  2026-04-08

  Leverage Losartan’s selective AT1 receptor blockade to dissect angiotensin II signaling, inhibit vascular smooth muscle cell proliferation, and modulate endothelial function in both cardiovascular and oncology research. Explore advanced in vitro and in vivo protocols, discover troubleshooting solutions, and unlock new translational potential with APExBIO’s rigorously validated Losartan (CAS 114798-26-4).

451 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page